Gastrin-releasing peptide receptors (GRPR) and GRP-derived analogs have attracted attention due to high receptor expression in frequently occurring human neoplasia. The authors recently synthesized a series of GRPR-affine peptide analogs based on the 27-mer GRP and derivatized with the DOTA chelator at the N-terminus for 111In-labeling. In this study, the authors evaluated the most promising from these series, DOTA-GRP(13–27), after radiolabeling with 177Lu for future therapeutic applications. In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [177Lu]DOTA-GRP(13–27) with the potent NEP inhibitor phosphoramidon (PA). The authors also aimed at reducing renal uptake by coadministration of lysine.
Methods:
In vivo stability studies were performed in Swiss albino mice. Biodistribution studies were conducted in NMRI nu/nu mice bearing prostate cancer (PC)-3 xenografts. Ex vivo autoradiography was performed using frozen sections from PC-3 xenografts and kidneys.
Results and Discussion:
Coadministration of PA significantly increased the percentage of intact radiopeptide in the mouse circulation. From biodistribution and ex vivo autoradiography studies, coadministration of both lysine and PA with [177Lu]DOTA-GRP(13–27) appeared to induce a clear improvement of tumor uptake as well as lower levels of renal radioactivity, causing a promising ninefold increase in tumor/kidney ratios.
Get full access to this article
View all access options for this article.
References
1.
ReubiJC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 2003; 24:389.
2.
FaniM, MaeckeHR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging, 2012; 39Suppl 1:S11.
3.
KrenningEP, KwekkeboomDJ, BakkerWH, et al.Somatostatin receptor scintigraphy with [111In-DTPA-DPhe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 1993; 20:716.
4.
GinjM, SchmittJS, ChenJ, et al.Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol, 2006; 13:1081.
5.
KwekkeboomDJ, Mueller-BrandJ, PaganelliG, et al.Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med, 2005; 46Suppl 1:62S–66S.
6.
KwekkeboomDJ, de HerberWW, KamBL, et al.Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy and survival. J Clin Oncol, 2008; 26:2124.
7.
GiovacchiniG, NicolasG, ForrerF. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Anticancer Agents Med Chem, 2012; 12:526.
8.
GuggerM, ReubiJC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol, 1999; 155:2067.
9.
MarkwalderR, ReubiJC. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res, 1999; 59:1152.
10.
SanchoV, Di FlorioA, MoodyTW. Bombesin receptor-mediated imaging and cytotoxicity: Review and current status. Curr Drug Deliv, 2011; 8:79.
11.
De VisserM, BernardHF, ErionJL, et al.Novel 111In-labeled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging, 2007; 34:1228.
12.
AnaniasHJ, de JongIJ, DierckxRA, et al.Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des, 2008; 14:3033.
13.
ZhangH, AbirajK, ThorekDL, et al.Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS One, 2012; 7:e44046.
14.
JohnsonCV, SheltonT, SmithCJ, et al.Evaluation of combined 177Lu-DOTA-8-AOC-BBN (7–14)NH2 GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm, 2006; 21:155.
15.
LantryLE, CappellettiE, MaddalenaME, et al.177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med, 2006; 47:1144.
16.
ZhangH, SchuhmacherJ, WaserB, et al.DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging, 2007; 34:1198.
17.
LinderKE, MetcalfeE, ArunachalamT, et al.In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem, 2009; 20:1171.
18.
MarsouvanidisPJ, MainaT, SalleggerW, et al.Tumor diagnosis with new (111)In-radioligands based on truncated human gastrin releasing peptide sequences: Synthesis and preclinical comparison. J Med Chem, 2013; 56:8579.
19.
MarsouvanidisPJ, MainaT, SalleggerW, et al.99mTc radiotracers based on human GRP(18–27): Synthesis and comparative evaluation. J Nucl Med, 2013; 54:1797.
20.
BunnettNW, KobayashiR, OrloffMS, et al.Catabolism of gastrin releasing peptide and substance P by gastric membrane-bound peptidases. Peptides, 1985; 6:277.
21.
ErdösEG, SkidgelRA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J, 1989; 3:145.
22.
ShippMA, TarrGE, ChenCY, et al.CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A, 1991; 88:10662.
23.
SudaH, AoyagiT, TakeuchiT, et al.Letter: A thermolysin inhibitor produced by Actinomycetes: Phosphoramidon. J Antibiot (Tokyo), 1973; 26:621.
24.
KomiyamaT, AoyagiT, TakeuchiT, et al.Inhibitory effects of phosphoramidon on neutral metalloendopeptidases and its application on affinity chromatography. Biochem Biophys Res Commun, 1975; 65:352.
25.
RoquesBP, NobleF, DauqeV, et al.Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev, 1993; 45:87.
26.
NowakW, ErrastiAE, ArmestoAR, et al.Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: An effective bradykinin inactivation pathway. Eur J Pharmacol, 2011; 667:271.
27.
NockBA, MainaT, KrenningEP, et al.“To serve and protect”: Enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med, 2014; 55:121.
28.
GotthardtM, van Eerd-VismaleJ, OyenWJ, et al.Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med, 2007; 48:596.
29.
MoestrupSK, CuiS, VorumH, et al.Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest, 1995; 96:1404.
30.
OrlandoRA, ExnerM, CzekayRP, et al.Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions. Proc Natl Acad Sci U S A, 1997; 94:2368.
31.
De JongM, BaroneR, KrenningEP, et al.Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med, 2005; 46:1696.
32.
VegtE, MelisM, EekA, et al.Renal uptake of different radiopeptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging, 2011; 38:623.
33.
BeheM, KlugeG, BeckerW, et al.Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med, 2005; 46:1012.
34.
VegtE, WetzelsJF, RusselFG, et al.Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med, 2006; 47:432.
35.
VegtE, van EerdJE, EekA, et al.Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med, 2008; 49:1506.
36.
VegtE, de JongM, WetzelsJF, et al.Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med, 2010; 51:1049.
37.
RollemanEJ, ValkemaR, de JongM, et al.Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging, 2003; 30:9–15.
38.
BodeiL, CremonesiM, ZoboliS, et al.Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging, 2003; 30:207.
39.
SchroederRPJ, de BloisE, de RidderCMA, et al.Improving radiopeptides pharmacokinetics by adjusting experimental conditions for bombesin receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging, 2012; 56:468.
40.
de BloisE, ChanHS, NaidooC, et al.Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. Appl Radiat Isot, 2011; 69:308.
41.
TokitaK, KatsunoT, HocartSJ, et al.Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem, 2001; 276:36652.
42.
UeharaH, GonzalezN, SanchoV, et al.Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs. Peptides, 2011; 32:1685.
43.
AzayJ, NagainC, LlinaresM, et al.Comparative study of in vitro and in vivo activities of bombesin pseudopeptide analogs modified on the C-terminal dipeptide fragment. Peptides, 1998; 19:57.
44.
NockB, NikolopoulouA, ChiotellisE, et al.[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging, 2003; 30:247.
45.
De VisserM, VerwijnenSM, de JongM. Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm, 2008; 23:137.
46.
SchroederRP, De BloisE, De RidderCM, et al.Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer. Q J Nucl Med Mol Imaging, 2012; 56:468.
47.
BreemanWAP, KwekkeboomDJ, KooijPM, et al.Effect of dose and specific activity on tissue distribution of Indium-111-pentetreotide in rats. J Nucl Med, 1995; 36:623.
